source
- Eli Lilly's $7B acquisition of Kelonia highlighted by full-cohort response in in-vivo CAR-T trial for multiple myelomaAt ASCO 2026, Kelonia Therapeutics presented data on its in-vivo CAR-T platform for multiple myeloma. The report covered 18 patients treated with the therapy, all of whom showed encouraging outcom…
- Servier acquires Edgewise's muscular dystrophy assets for $1.55 billionServier announced it will purchase the muscular dystrophy business from Edgewise Therapeutics. The deal involves an upfront payment of $1.55 billion, giving the French company rights to Edgewise's…